Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alzamend Neuro Inc (NQ: ALZN ) 1.490 -0.010 (-0.67%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 83,525 Open 1.480 Bid (Size) 1.460 (6) Ask (Size) 1.520 (5) Prev. Close 1.500 Today's Range 1.450 - 1.530 52wk Range 1.400 - 19.20 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s October 16, 2024 Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease Via PressReach Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s October 16, 2024 From Alzamend Neuro, Inc. Via Business Wire Performance YTD -83.80% -83.80% 1 Month -6.88% -6.88% 3 Month -32.27% -32.27% 6 Month -70.50% -70.50% 1 Year -89.79% -89.79% More News Read More EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's October 16, 2024 Via Benzinga Alzamend Neuro Regains Compliance with Nasdaq Listing Standards October 15, 2024 Via PressReach Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference October 10, 2024 Via PressReach Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket August 20, 2024 Via Benzinga Alzamend Neuro Regains Compliance with Nasdaq Listing Standards October 15, 2024 From Alzamend Neuro, Inc. Via Business Wire Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today August 19, 2024 Via Benzinga Topics Stocks Exposures US Equities Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference October 10, 2024 From Alzamend Neuro, Inc. Via Business Wire Nasdaq Surges 150 Points; Sonder Holdings Shares Surge August 19, 2024 Via Benzinga Alzamend Neuro Issues Letter to Stockholders August 26, 2024 From Alzamend Neuro Via Business Wire Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session August 19, 2024 Via Benzinga Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher August 19, 2024 Via Benzinga Exposures Fossil Fuels Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder August 19, 2024 Via PressReach Exposures Product Safety Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results August 19, 2024 Via Benzinga Topics Stocks Exposures US Equities Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details August 19, 2024 Via Benzinga Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder August 19, 2024 From Alzamend Neuro, Inc. Via Business Wire New Study Reveals How Classical Music Could Revolutionize Depression Care August 12, 2024 Via PressReach Exposures Product Safety Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder August 12, 2024 Via PressReach Exposures Product Safety Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder August 12, 2024 Via PressReach Exposures Product Safety Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder August 12, 2024 Via News Direct Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder August 12, 2024 From Alzamend Neuro, Inc. Via Business Wire Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease August 06, 2024 Via News Direct Exposures Product Safety Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment August 06, 2024 Via PressReach Exposures Product Safety Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease August 06, 2024 Via PressReach Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
